论文部分内容阅读
目的评价前列腺素E1治疗急性胰腺炎的临床疗效和安全性。方法通过计算机检索全面收集(1966年1月至2008年10月)全世界关于前列腺素E1治疗急性胰腺炎的随机对照试验或半随机对照试验,并辅手工检索和其他检索。按照纳入排除标准纳入文献,由2名研究者独立筛选并提取资料,采用Handbook4.2.6推荐的质量评价标准评价纳入研究的质量,采用Rev Man4.2.10软件进行统计学处理。结果最终纳入5项研究310例病人。Meta分析结果显示前列腺素E1+常规治疗组与常规治疗组比较,在腹痛缓解时间、腹痛完全消失时间、血清淀粉酶恢复正常时间、治愈时间方面差异有统计学意义。结论当前研究显示,前列腺素E1+常规治疗能显著缩短急性胰腺炎病人的腹痛缓解时间、腹痛完全消失时间、血清淀粉酶恢复正常时间和治愈时间。
Objective To evaluate the clinical efficacy and safety of prostaglandin E1 in the treatment of acute pancreatitis. METHODS: All computerized randomized controlled trials or semi-randomized controlled trials of prostaglandin E1 for the treatment of acute pancreatitis were collected worldwide (January 1966 to October 2008) and were searched manually and manually. According to inclusion criteria, the two researchers independently screened and extracted data, and the quality of the included studies was evaluated using the quality evaluation criteria recommended by Handbook 4.2.6. The data were analyzed by using Rev Man 4.2.10 software. Results The final study enrolled 310 patients in 5 studies. Meta analysis showed that the prostaglandin E1 + routine treatment group compared with the conventional treatment group, in the abdominal pain relief time, abdominal pain disappeared completely, serum amylase recovery time, healing time difference was statistically significant. Conclusions The current study shows that prostaglandin E1 + can significantly reduce the pain relief time, complete disappearance of abdominal pain, serum amylase recovery time and cure time in acute pancreatitis patients.